The International Space Station Research and Development Conference is set to showcase the latest scientific advancements and future prospects in cancer research, regenerative medicine, and in-space manufacturing. The session, titled "Trailblazing New Frontiers in Science on the Space Station," will bring together pioneers in transformative research with clinical applications to discuss how the International Space Station is accelerating discoveries within the biomedical community.
Co-moderated by Jennifer Buchli, NASA chief scientist for the ISS Program, and Michael Roberts, chief scientific officer for the ISS National Laboratory, the session will feature a panel of experts from leading institutions and companies. Both NASA and the ISS National Lab have prioritized the utilization of the space station for cancer and other disease-related research, as well as in-space production applications and manufacturing opportunities.
Among the panelists is Tony Atala, G. Link professor and director of the Wake Forest Institute for Regenerative Medicine. Atala will lead a team of researchers launching multiple space station investigations focused on the vascularization of bioprinted tissue, sponsored by the ISS National Lab after originating through NASA's Vascular Tissue Challenge. This groundbreaking research has the potential to revolutionize tissue engineering and regenerative medicine.
Catriona Jamieson, director of the Sanford Stem Cell Institute at the University of California, San Diego, will also share her insights. Jamieson has led multiple ISS National Lab-sponsored investigations focused on cancer and has worked with commercial astronauts through Axiom Space to uncover new insights into protecting astronaut health while improving cancer treatment on Earth. Her research aims to leverage the unique environment of the ISS to develop novel therapies for cancer patients.
The session will also feature Adrian Radocea, chief science officer at Varda Space Industries, which successfully completed its first mission to crystallize therapeutics in its free-flying spacecraft in low Earth orbit. This milestone opens new and exciting possibilities for in-space biopharmaceutical development, potentially leading to the discovery of new drugs and treatments.
Kenneth Savin, chief scientific officer for Redwire Space, will discuss the company's recent achievements in space-based manufacturing. Redwire has developed various space station facilities available to the research community and recently used its BioFabrication Facility to successfully print the first human meniscus and cardiac tissue in space. The company also validated its Pharmaceutical In-space Laboratory by collaborating with Eli Lilly and Company, recently returning 36 crystallography investigations designed for potential pharmaceutical use.
Michael Roberts, chief scientific officer for the ISS National Lab, expressed his enthusiasm for the upcoming session, stating, "We are privileged to have these leaders in biomedical research and in-space manufacturing join us at ISSRDC to share their recent discoveries and perspectives on the next decade of results. We look forward to an engaging conversation about how low Earth orbit provides a unique environment to accelerate the diagnosis, prevention, and treatment of disease and opens novel pathways for drug development to benefit humans on Earth and those living and working off our planet."
ISSRDC, hosted by the Center for the Advancement of Science in Space, manager of the ISS National Lab, NASA, and the American Astronautical Society, is the only conference dedicated to showcasing our nation's orbiting laboratory and the growing market economy in low Earth orbit. The conference will take place at the Boston Marriott Copley Place from July 29 through August 1 and will feature a series of keynote speakers, panel sessions, lightning talks, plenary presentations, technical sessions, workshops, an investor session, and networking opportunities.
NASDAQ: ISSNL
Price: $52.75
Change: 4.2%
The stock is currently in an uptrend, with strong support at $50.00 and resistance at $55.00. The 50-day moving average is $48.50, and the stock is trading above this level, indicating a bullish sentiment. The MACD indicator shows a positive crossover, suggesting momentum in the stock's favor. Fibonacci retracement levels indicate potential support at $51.80 (38.2% retracement) and $50.20 (61.8% retracement). Bollinger Bands are narrowing, which may suggest a period of lower volatility in the near term. Overall, the technical analysis suggests a positive outlook for the ISS National Lab's stock, with the potential for further upside as the organization continues to showcase the advancements and opportunities in low Earth orbit through events like ISSRDC.
